Journal
BIOMARKERS IN MEDICINE
Volume 8, Issue 9, Pages 1127-1137Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.14.72
Keywords
antibody; biomarkers; Helicobacter pylori; miRNA
Categories
Funding
- NIH [DK62813]
- Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [22390085, 22659087, 24406015, 24659200, 23790798]
- Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation for Japan Society for the Promotion of Science (JSPS)
- Strategic Funds for the Promotion of Science and Technology from Japan Science and Technology Agency (JST)
- Grants-in-Aid for Scientific Research [26640114, 24406015, 23790798, 25293104, 25860544] Funding Source: KAKEN
Ask authors/readers for more resources
Helicobacter pylori infection is a major cause of gastric cancer. Although identifying H. pylori infected subjects is the first approach for delineating the high-risk population for gastric cancer, the presence of H. pylori antibodies is not sufficient for gastric cancer screening. Among H. pylori infected subjects, only a minority of infected individuals develop gastric cancer. Serologic markers of H. pylori infection can serve as potential predictors for the development of gastric cancer. Serum or urinary H. pylori antibodies, cytotoxin-associated gene A antibodies, pepsinogen and microRNAs were reported to be associated with precancerous lesions or gastric cancer. In this review, we summarized the utilities and limitations of each strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available